Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04967391 · ClinicalTrials.gov registry record · Phase 3
Tumescence in HNC Skin Graft Reconstruction
A Phase 3 study of Head and Neck Cancer and Surgery--Complications, sponsored by University of California, Davis.
- Active
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT04967391 is a Phase 3 study of Head and Neck Cancer and Surgery--Complications that is active but no longer recruiting, run by University of California, Davis. The registered enrollment target is 58 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04967391, a Phase 3 study of Head and Neck Cancer and Surgery--Complications, is active but no longer recruiting, sponsored by University of California, Davis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
Our primary objective is to determine if the use of tumescence has a meaningful effect on STSG uptake at the recipient site. This is an important outcome because poor graft uptake results in the need for prolonged local wound care, additional clinic visits for patients and increased risk of infection. A prospective, randomized comparison of the tumescence to our current standard of care will allow us to definitively evaluate any benefits to this technique. Tumescence is commonly used in the treatment of burn patients to minimize blood loss during both tangential excision of eschar and during harvest of split-thickness grafts for reconstruction. This is considered the standard of care in burn surgery as using tumescence has been clearly demonstrated to reduce intraoperative blood loss during harvest of large skin grafts and excision of large burns when compared with the application of topical epinephrine as was the historic standard practice.4-6 Tumescence also creates a firm and uniform surface from which to harvest the skin graft, which the investigators believe may improve the quality of harvest and rate of skin graft take.
Conditions Studied
Interventions
- PROCEDURE Tumescence During STSG Harvest
Study Locations (1)
California
- UC Davis Health - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04967391
The ClinicalTrials.gov registry entry for NCT04967391 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (78% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tumescence During STSG Harvest is the first listed.
NCT04967391 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04967391 about?
NCT04967391 is a clinical study titled "Tumescence in HNC Skin Graft Reconstruction". Our primary objective is to determine if the use of tumescence has a meaningful effect on STSG uptake at the recipient site. This is an important outcome because poor graft uptake results in the need for prolonged local wound care, additional clinic visits for patients and increased risk of infectio...
What is the current status of trial NCT04967391?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2021-09-01. Estimated completion is 2026-08-30.
What conditions does trial NCT04967391 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Surgery--Complications, Graft Failure.
What interventions are being tested in trial NCT04967391?
The interventions under investigation include: Tumescence During STSG Harvest (PROCEDURE).
Who is sponsoring clinical trial NCT04967391?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04967391 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
RECRUITING · Phase 3
-
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
ACTIVE NOT RECRUITING · Phase 3
-
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
ACTIVE NOT RECRUITING · Phase 3
-
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
COMPLETED · Phase 3
-
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.